Other Events ·
PolyPid Ltd. filed its interim financial statements for the six months ended June 30, 2026, reporting a net loss of…
PYPDPolyPid Ltd.
PolyPid Ltd. filed its interim financial statements for the six months ended June 30, 2026, reporting a net loss of $15.6 million and cash reserves of $6.6 million. The company entered into a license and supply agreement with Azurity Pharmaceuticals on July 17, 2026, granting exclusive U.S. and Canadian commercialization rights to its product D-PLEX 100 in exchange for a $15 million upfront payment and up to $290 million in potential milestones. PolyPid operates as an innovative biopharmaceutical company developing long-acting controlled-release medicines.